stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Revenue growth
GeneDx Holdings Corp.'s revenue growth over the twelve months to 30 June 2026 was 25.4%, down 14.6 percentage points from fiscal 2025 (40.0%). Over the past ten years it has ranged from −13.7% (fiscal 2023) to 50.8% (fiscal 2024); the current reading is higher than 86% of that period. That is above the Diagnostics & Research industry median of 8.99% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 40.0% | (10.82) |
| FY2024 | 50.8% | 64.48 |
| FY2023 | −13.7% | (24.29) |
| FY2022 | 10.6% | (7.73) |
| FY2021 | 18.3% | 26.92 |
| FY2020 | −8.59% | (17.99) |
| FY2019 | 9.40% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 11.4% | (5.94) |
| Mar 2026 | 17.4% | (9.12) |
| Dec 2025 | 26.5% | (25.36) |
| Sep 2025 | 51.9% | 6.23 |
| 15 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| CDNA CareDx, Inc. compare | 38.9% |
| WGS GeneDx Holdings Corp. | 25.4% |
| ADPT Adaptive Biotechnologies Corporation compare | 17.9% |
| VCYT Veracyte, Inc. compare | 17.5% |
| PSNL Personalis, Inc. compare | 16.9% |
| NEO NeoGenomics, Inc. compare | 11.1% |
| CSTL Castle Biosciences, Inc. compare | 9.78% |
| OPK OPKO Health, Inc. compare | −21.9% |
| FRNM Freenome, Inc compare | — |
| Diagnostics & Research industry median | 8.99% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement